Data-Efficient Computational Pathology Platform for Faster and Cheaper Breast Cancer Subtype Identifications: Development of a Deep Learning Model.

IF 3.3 Q2 ONCOLOGY JMIR Cancer Pub Date : 2023-09-05 DOI:10.2196/45547
Kideog Bae, Young Seok Jeon, Yul Hwangbo, Chong Woo Yoo, Nayoung Han, Mengling Feng
{"title":"Data-Efficient Computational Pathology Platform for Faster and Cheaper Breast Cancer Subtype Identifications: Development of a Deep Learning Model.","authors":"Kideog Bae,&nbsp;Young Seok Jeon,&nbsp;Yul Hwangbo,&nbsp;Chong Woo Yoo,&nbsp;Nayoung Han,&nbsp;Mengling Feng","doi":"10.2196/45547","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer subtyping is a crucial step in determining therapeutic options, but the molecular examination based on immunohistochemical staining is expensive and time-consuming. Deep learning opens up the possibility to predict the subtypes based on the morphological information from hematoxylin and eosin staining, a much cheaper and faster alternative. However, training the predictive model conventionally requires a large number of histology images, which is challenging to collect by a single institute.</p><p><strong>Objective: </strong>We aimed to develop a data-efficient computational pathology platform, 3DHistoNet, which is capable of learning from z-stacked histology images to accurately predict breast cancer subtypes with a small sample size.</p><p><strong>Methods: </strong>We retrospectively examined 401 cases of patients with primary breast carcinoma diagnosed between 2018 and 2020 at the Department of Pathology, National Cancer Center, South Korea. Pathology slides of the patients with breast carcinoma were prepared according to the standard protocols. Age, gender, histologic grade, hormone receptor (estrogen receptor [ER], progesterone receptor [PR], and androgen receptor [AR]) status, erb-B2 receptor tyrosine kinase 2 (HER2) status, and Ki-67 index were evaluated by reviewing medical charts and pathological records.</p><p><strong>Results: </strong>The area under the receiver operating characteristic curve and decision curve were analyzed to evaluate the performance of our 3DHistoNet platform for predicting the ER, PR, AR, HER2, and Ki67 subtype biomarkers with 5-fold cross-validation. We demonstrated that 3DHistoNet can predict all clinically important biomarkers (ER, PR, AR, HER2, and Ki67) with performance exceeding the conventional multiple instance learning models by a considerable margin (area under the receiver operating characteristic curve: 0.75-0.91 vs 0.67-0.8). We further showed that our z-stack histology scanning method can make up for insufficient training data sets without any additional cost incurred. Finally, 3DHistoNet offered an additional capability to generate attention maps that reveal correlations between Ki67 and histomorphological features, which renders the hematoxylin and eosin image in higher fidelity to the pathologist.</p><p><strong>Conclusions: </strong>Our stand-alone, data-efficient pathology platform that can both generate z-stacked images and predict key biomarkers is an appealing tool for breast cancer diagnosis. Its development would encourage morphology-based diagnosis, which is faster, cheaper, and less error-prone compared to the protein quantification method based on immunohistochemical staining.</p>","PeriodicalId":45538,"journal":{"name":"JMIR Cancer","volume":"9 ","pages":"e45547"},"PeriodicalIF":3.3000,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509735/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIR Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/45547","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Breast cancer subtyping is a crucial step in determining therapeutic options, but the molecular examination based on immunohistochemical staining is expensive and time-consuming. Deep learning opens up the possibility to predict the subtypes based on the morphological information from hematoxylin and eosin staining, a much cheaper and faster alternative. However, training the predictive model conventionally requires a large number of histology images, which is challenging to collect by a single institute.

Objective: We aimed to develop a data-efficient computational pathology platform, 3DHistoNet, which is capable of learning from z-stacked histology images to accurately predict breast cancer subtypes with a small sample size.

Methods: We retrospectively examined 401 cases of patients with primary breast carcinoma diagnosed between 2018 and 2020 at the Department of Pathology, National Cancer Center, South Korea. Pathology slides of the patients with breast carcinoma were prepared according to the standard protocols. Age, gender, histologic grade, hormone receptor (estrogen receptor [ER], progesterone receptor [PR], and androgen receptor [AR]) status, erb-B2 receptor tyrosine kinase 2 (HER2) status, and Ki-67 index were evaluated by reviewing medical charts and pathological records.

Results: The area under the receiver operating characteristic curve and decision curve were analyzed to evaluate the performance of our 3DHistoNet platform for predicting the ER, PR, AR, HER2, and Ki67 subtype biomarkers with 5-fold cross-validation. We demonstrated that 3DHistoNet can predict all clinically important biomarkers (ER, PR, AR, HER2, and Ki67) with performance exceeding the conventional multiple instance learning models by a considerable margin (area under the receiver operating characteristic curve: 0.75-0.91 vs 0.67-0.8). We further showed that our z-stack histology scanning method can make up for insufficient training data sets without any additional cost incurred. Finally, 3DHistoNet offered an additional capability to generate attention maps that reveal correlations between Ki67 and histomorphological features, which renders the hematoxylin and eosin image in higher fidelity to the pathologist.

Conclusions: Our stand-alone, data-efficient pathology platform that can both generate z-stacked images and predict key biomarkers is an appealing tool for breast cancer diagnosis. Its development would encourage morphology-based diagnosis, which is faster, cheaper, and less error-prone compared to the protein quantification method based on immunohistochemical staining.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用于更快、更便宜的癌症亚型识别的高效数据计算病理学平台:深度学习模型的开发。
背景:乳腺癌症分型是确定治疗方案的关键步骤,但基于免疫组织化学染色的分子检查昂贵且耗时。深度学习为基于苏木精和伊红染色的形态学信息预测亚型开辟了可能性,这是一种更便宜、更快的替代方法。然而,训练预测模型通常需要大量的组织学图像,这对于单个研究所来说是一个挑战。目的:我们旨在开发一个数据高效的计算病理学平台3DHistoNet,该平台能够从z堆叠的组织学图像中学习,以小样本量准确预测乳腺癌症亚型。方法:我们回顾性检查了2018年至2020年间在韩国国家癌症中心病理科诊断的401例原发性乳腺癌患者。根据标准方案制备乳腺癌患者的病理切片。年龄、性别、组织学分级、激素受体(雌激素受体[ER]、孕激素受体[PR]和雄激素受体[AR])状态、erb-B2受体酪氨酸激酶2(HER2)状态和Ki-67指数通过查阅病历和病理记录进行评估。结果:分析受试者操作特征曲线和决策曲线下面积,以评估我们的3DHistoNet平台在预测ER、PR、AR、HER2和Ki67亚型生物标志物方面的性能,并进行5倍交叉验证。我们证明3DHistoNet可以预测所有临床上重要的生物标志物(ER、PR、AR、HER2和Ki67),其性能大大超过传统的多实例学习模型(受试者操作特征曲线下面积:0.75-0.91 vs 0.67-0.8)。我们进一步证明,我们的z堆栈组织学扫描方法可以弥补训练数据不足的不足无需任何额外费用。最后,3DHistoNet提供了生成注意力图的额外功能,该功能揭示了Ki67和组织形态学特征之间的相关性,从而使苏木精和伊红图像对病理学家具有更高的保真度。结论:我们的独立、数据高效的病理学平台既可以生成z叠加图像,又可以预测关键生物标志物,是癌症诊断的一个有吸引力的工具。它的发展将鼓励基于形态学的诊断,与基于免疫组织化学染色的蛋白质定量方法相比,这种方法更快、更便宜、更不容易出错。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
JMIR Cancer
JMIR Cancer ONCOLOGY-
CiteScore
4.10
自引率
0.00%
发文量
64
审稿时长
12 weeks
期刊最新文献
Experiences of a Digital Behavior Change Intervention to Prevent Weight Gain and Promote Risk-Reducing Health Behaviors for Women Aged 18 to 35 Years at Increased Risk of Breast Cancer: Qualitative Interview Study. Scope, Findability, and Quality of Information About Music-Based Interventions in Oncology: Quantitative Content Analysis of Public-Facing Websites at National Cancer Institute-Designated Cancer Centers. Oral Cancer Incidence Among Adult Males With Current or Former Use of Cigarettes or Smokeless Tobacco: Population-Based Study. Uncovering the Daily Experiences of People Living With Advanced Cancer Using an Experience Sampling Method Questionnaire: Development, Content Validation, and Optimization Study. Impact of Patient Personality on Adherence to Oral Anticancer Medications: An Opportunity?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1